GSK partners with Alamar on proteomics study using more than 60,000 samples
AI Summary- GSK partnered with Alamar Biosciences on a large proteomics study.
- More than 60,000 serum samples will be processed across five disease areas.
- GSK shares stood at £19.01 against Simply Wall St’s £21.73 fair-value estimate.